Quetiapine: Another drug with potential for misuse? A case report

Journal of Clinical Psychiatry

Volumn 69, Issue 1, 2008, Pages 162-163

  Paparrigopoulos, Thomas ^a   Karaiskos, Dimitris ^a   Liappas, John ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BROMAZEPAM; CLONAZEPAM; QUETIAPINE; VITAMIN;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL INTOXICATION; ALCOHOLISM; ANXIETY DISORDER; CASE REPORT; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; FOLLOW UP; HUMAN; LETTER; MALE; PRIORITY JOURNAL;

EID: 39549090847     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0122a     Document Type: Letter

References (18)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. In: Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2000. Washington, DC: American Psychiatric Association; 2000:628-662
2. Potvin S, Stip E, Roy JY. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 2003;18:121-132
3. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 2004;29:452-457
4. Liappas J, Paparrigopoulos T, Tzavellas E, et al. Amisulpride may help alcoholics in the early postdetoxification phase. J Clin Psychopharmacol 2005;25:396-398
5. Croissant B, Klein O, Gehrlein L, et al. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiatry 2006;21:570-573
6. Monnelly EP, Ciraulo DA, Knapp C, et al. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol 2004;24:532-535
7. Goldstein BI, Diamantouros A, Schaffer A, et al. Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders. Drugs 2006;66:1229-1237
8. Pierre JM, Shnayder I, Wirshing DA, et al. Intranasal quetiapine abuse. Am J Psychiatry 2004;161:1718
9. Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse. Am J Psychiatry 2005;162:1755-1756
10. Pinta ER, Taylor RE. Quetiapine addiction? Am J Psychiatry 2007;164:174-175
11. Morin AK. Possible intranasal quetiapine misuse. Am J Health Syst Pharm 2007;64:723-725
12. Tarasoff G, Osti K. Black-market value of antipsychotics, antidepressants, and hypnotics in Las Vegas, Nevada. Am J Psychiatry 2007;164:350
13. Hyman SE, Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2001;2:695-703
14. Tupala E, Tiihonen J. Dopamine and alcoholism: neurobiological basis of ethanol abuse. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1221-1247
15. Wiesbeck GA, Weijers HG, Lesch OM, et al. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol 2001;36:329-334
16. Ohuoha DC, Maxwell JA, Thomson LE 3rd, et al. Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study. J Subst Abuse Treat 1997;14:249-258
17. AstraZeneca. Seroquel: summary of product characteristics. July 2007. Available at: http://www.seroquel.info/_mshost514871/content/856032/Product- Characteristics. Accessibility verified November 16, 2007
18. Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002;63:992-997